Plans, designs, and analyses for clinical trials of anti-cocaine medications: where we are today. NIDA/VA/SU Working Group on Design and Analysis

P W Lavori; D A Bloch; P T Bridge; D B Leiderman; J S LoCastro; E Somoza

doi:10.1097/00004714-199906000-00008

Plans, designs, and analyses for clinical trials of anti-cocaine medications: where we are today. NIDA/VA/SU Working Group on Design and Analysis

J Clin Psychopharmacol. 1999 Jun;19(3):246-56. doi: 10.1097/00004714-199906000-00008.

Authors

P W Lavori¹, D A Bloch, P T Bridge, D B Leiderman, J S LoCastro, E Somoza

Affiliation

¹ VA Cooperative Studies Program, Palo Alto VAHCS, California 94304, USA. lavori@odd.stanford.edu

PMID: 10350031
DOI: 10.1097/00004714-199906000-00008

Abstract

Increased interest in addiction psychopharmacology has raised unique methodologic issues in the design, conduct, and analysis of outcomes in clinical trials of therapeutic agents for drug dependence. This article summarizes issues raised at a meeting in Palo Alto, California, on November 4, 1996, that was sponsored by the Medication Development Division of the National Institute on Drug Abuse and the Department of Veterans Affairs Cooperative Studies Program to discuss the methodologic issues in clinical trials of cocaine pharmacotherapy.

Publication types

Research Support, U.S. Gov't, Non-P.H.S.
Research Support, U.S. Gov't, P.H.S.

MeSH terms

Behavior Therapy
Clinical Trials as Topic*
Cocaine-Related Disorders / drug therapy*
Humans
Outcome and Process Assessment, Health Care
Patient Compliance
Research Design*

Grants and funding

Y01DA 40032/DA/NIDA NIH HHS/United States